Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

Andre F., O'Regan R., Ozguroglu M., Toi M., Xu B., Jerusalem G., ...Daha Fazla

LANCET ONCOLOGY, cilt.15, sa.6, ss.580-591, 2014 (SCI-Expanded, Scopus) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 6
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1016/s1470-2045(14)70138-x
  • Dergi Adı: LANCET ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.580-591
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background Disease progression in patients with HER2-positive breast cancer receiving trastuzumab might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. We aimed to assess whether the addition of the mTOR inhibitor everolimus to trastuzumab might restore sensitivity to trastuzumab.